Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CXCL16-driven CD4+ T cells orchestrate immunosurveillance against MHC-I-deficient tumors

ABSTRACT: MHC-I loss is a prevalent mechanism for immune evasion and resistance to immunotherapy. However, the mechanisms by which MHC-I loss shapes the tumor microenvironment (TME) and influences the interactions between MHC-I-deficient tumors and immune cells, ultimately affecting tumor growth, remain largely unknown. Here, we found that MHC-I/B2M loss increased tumor growth rates in the MC38, AKR and LLC1 tumor models, but surprisingly led to regression of Hepa1-6 tumors. The effect of MHC-I/B2M loss on tumor growth was associated with the changes in immune infiltrates. CD4+ T cell, NK cells and macrophages were required to suppress the growth of MHC-I-deficient Hepa1-6 tumors, with CD4+ T cells appearing essential for maintaining of the tumoricidal phenotype of monocytes/macrophages and for recruiting NK cells and monocytes/macrophages. Moreover, the differential infiltration of CD4+ T cells was attributed to the upregulation of CXCL16 expression in Hepa1-6 upon loss of MHC-I/B2M, and the downregulation of CXCL16 due to MHC-I deficiency in other tumor models. CXCL16 exhibited a potent antitumor effect on MHC-I-deficient tumors by recruiting CD4+ T cells. In summary, CXCL16-driven CD4+ T cells are central regulators of antitumor immunity against MHC-I-deficient tumors.

ORGANISM(S): Mus musculus

PROVIDER: GSE303349 | GEO | 2026/03/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CXCL16-driven CD4+ T cells orchestrate immunosurveillance against MHC-I-deficient tumors

Project description:CXCL16-driven CD4+ T cells orchestrate immunosurveillance against MHC-I-deficient tumors

| PRJNA1294882 | ENA

Transcriptional profiling of tumor microenvironment in B2M KO CD40-treated B16 tumors implanted in mice

Project description:The immune changes induced by loss of antigen presentation by tumor cells, a common mechanism of acquired resistance to immunotherapy, as well as the mechanisms by which CD40 agonist treatment controls the growth of B2m-null tumors, are unknown. We performed single-cell RNA-seq of total tumor-infiltrating immune cells in control and B2m-null tumors treated with isotype control or CD40 agonist antibodies to identify changes in immune cell states due to tumor cell loss of B2m and agonist CD40 treatment.

2026-02-02 | GSE240148 | GEO

Downregulation of CD109 on melanoma cells reduces ICI efficacy by inducing TIL resistance in melanoma cells during the effector phase

Project description:Although immune checkpoint inhibitors (ICIs) have improved the prognosis of melanoma, overcoming acquired resistance remains a challenge. The most critical mechanism is B2M mutation-mediated major histocompatibility complex (MHC) class I loss. Conversely, resistance mechanisms other than B2M mutations might be surmountable, although most of them are not yet fully understood. This study aimed to explore the novel mechanisms of acquired resistance in the absence of MHC class I loss. Previously, we established a pair of melanoma cell lines and cultured tumor-infiltrating lymphocytes (TILs) derived from an ICI-resistant melanoma patient with B2M mutation. Autologous TILs were unable to recognize the melanoma cells (MEL01), although genetic transduction of wild-type B2M (MEL01-B2M) reversed this phenomenon. To identify resistance mechanisms other than B2M mutation, we generated TIL-resistant MEL01-B2M cells by in vitro long-term co-culture (MEL01-B2M-R) and compared gene expression profiles between MEL01-B2M and MEL01-B2M-R. CD109 expression in MEL01-B2M-R cells was reduced by < 20%. Although CD109 has attracted attention as a negative regulator of transforming growth factor beta in allergic diseases, its effect on TILs, which play a central role in the efficacy of ICIs, remains unknown. Immunohistochemical analysis of 142 patients with melanoma revealed that low CD109 expression was associated with poor prognosis, regardless of MHC class I retention in melanoma tissues. In the co-culture assay, the knockout of CD109 in melanoma cells significantly impaired recognition and killing by specific TILs. These findings suggest that CD109 may serve as a predictive biomarker of ICI efficacy and as a novel therapeutic target for overcoming ICI resistance.

2025-09-30 | GSE309150 | GEO

CD4+ T-cell-induced inflammatory killing controls immune evasive tumors

Project description:Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T-cells to directly recognise and kill tumor cells. These strategies are limited by the emergence of MHC-deficient tumor cells and the development of an immunosuppressive tumor microenvironment. The ability of CD4+ effector cells to contribute to anti-tumor immunity independently of CD8+ T-cells is increasingly recognised, but strategies to unleash their full potential remain to be identified. Here, we describe a mechanism through which a small number of CD4+ T-cells is sufficient to eradicate MHC-deficient tumors that escape direct CD8+ T-cell targeting. The CD4+ effector T-cells preferentially cluster at tumor invasive margins where they interact with MHC-II+CD11c+ antigen-presenting cells. We show that Th1-directed CD4+ T-cells and innate immune stimulation reprogram the tumor-associated myeloid cell network towards IFN-activated antigen-presenting and iNOS-expressing tumoricidal effector phenotypes. Together, CD4+ T-cells and tumoricidal myeloid cells orchestrate a remote inflammatory cell death process that indirectly eradicates IFN-unresponsive and MHC-deficient tumors. These results warrant to clinically exploit the ability of CD4+ T-cells and innate immune stimulators as a strategy to complement the direct cytolytic activity of CD8+ T- and NK-cells and advance cancer immunotherapies.

2023-05-24 | GSE230427 | GEO

β2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages

Project description:Glioblastoma (GBM) is a complex ecosystem that includes a heterogeneous tumor population and the tumor immune microenvironment (TIME), prominently containing tumor- associated macrophages (TAM) and microglia. Here, we dem- onstrated that β2-microglobulin (B2M), a subunit of the class I major histocompatibility complex (MHC-I), promotes the maintenance of stem-like neoplastic populations and repro- grams the TIME to an anti-inflammatory, tumor-promoting state. B2M activated PI3K/AKT/mTOR signaling by interacting with PIP5K1A in GBM stem cells (GSC) and promoting MYC- induced secretion of transforming growth factor-β1 (TGFβ1). Inhibition of B2M attenuated GSC survival, self-renewal, and tumor growth. B2M-induced TGFβ1 secretion activated para- crine SMAD and PI3K/AKT signaling in TAMs and promoted an M2-like macrophage phenotype. These findings reveal tumor-promoting functions of B2M and suggest that targeting B2M or its downstream axis may provide an effective approach for treating GBM.

2022-06-30 | GSE203074 | GEO

Gene expression analysis of blood cells and tumor

Project description:This SuperSeries is composed of the following subset Series: GSE38976: Gene expression profiles of whole blood cells and the fraction enriched with tumor-infiltrating inflammatory cells of Balb/c athymic mice with Hepa1-6 tumors GSE38979: Gene expression profiles of blood and the enriched fraction of tumor-infiltrating inflammatory cells of C57Bl/6 mice with Hepa1-6 tumors GSE38980: Gene expression profiles of whole blood cells of C57Bl/6 mice with Hepa1-6 tumors GSE38981: Gene expression profiles of Hepa1-6 tumors in C57Bl/6 mice Refer to individual Series

2012-07-02 | E-GEOD-39075 | biostudies-arrayexpress

Targeting Truncated O-Glycan Elicits Dual T Cell Immunity and Overcomes MHC-I Heterogeneity to Design Effective Cancer Vaccine

Project description:Aberrant O-glycosylation is a hallmark of cancer, but its contribution to immune evasion is unclear. Using CRISPR–Cas9 to delete GalNAc-transferases, particularly Galnt7, in tumor cells, we reduced mucin-type O-glycan truncation. This remodeling activated dendritic cell– and T cell–dependent immunity, eradicating established tumors, preventing metastasis, and generating durable memory. It enhanced clearance of MHC class I–positive tumors via coordinated CD8⁺ and CD4⁺ T cell responses, and uniquely enabled CD4⁺ T cell–mediated elimination of MHC class I–deficient tumors, which evade cytotoxic T lymphocyte surveillance. Tumor cells with reduced O-glycan truncation served as potent whole-cell vaccines, with efficacy further improved by radiotherapy. These findings establish glycosylation as a central regulator of tumor immune evasion and define a broadly applicable vaccine platform that bypasses the limitations of neoantigen-based approaches for low-immunogenicity cancers.

2025-10-02 | GSE309508 | GEO

Intra-tumoral Treg Ablation Activates a CD4-NK Cell Axis to Control CD8 T cell Resistant Tumors

Project description:Tumors evade control by CD8+ T cells by losing MHC I expression, necessitating new approaches to improve immunotherapy. NK cells target MHC I-deficient cells but are insufficiently activated to control tumors without help. Here we uncovered a novel approach to control MHC I-deficient tumors by ablating Treg cells intratumorally, which incites potent antitumor NK cell responses without imparting lethal autoimmunity. IT-Treg ablation increased NK cell activation, maturation, expression of effector molecules, and anti-tumor cytotoxic activity. In this setting, conventional CD4+ T cells were required for NK cell activation, due to their production of IL-2 after interacting with conventional type 2 dendritic cells. These results demonstrate an opportunity to reinvigorate antitumor NK cell responses against tumors that evade CD8 T cell responses, by locally depleting Tregs. The findings also highlight the multicellular immunosuppression enforced by Tregs that extends beyond the control of CD8 T cell responses to tumors.

2025-08-01 | GSE287581 | GEO

cIAP1/2 antagonism eliminates MHC class I negative tumors through T cell-dependent reprogramming of mononuclear phagocytes

Project description:Induction of non-canonical NF-kB signaling with IAP antagonists mimics costimulatory signaling, augmenting anti-tumor immunity. We show that induction of non-canonical NF-kB signaling induces T-cell dependent immune responses even in B2M-null tumors, demonstrating that direct CD8 T cell recognition of tumor cell expressed MHC class I is not required. Instead, T cell-produced cytokines reprogram macrophages to be tumoricidal. We characterized by single-cell RNA-Seq the transcriptional profile of immune cells infilitrating mouse pancreatic tumors treated with the IAP anatagonist LCL161.

2021-04-30 | GSE150271 | GEO

Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines

Project description:Tumor heterogeneity is a major barrier to cancer therapy, including immunotherapy. Activated T cells can efficiently kill tumor cells following recognition of MHC class I (MHC-I) bound peptides, but this selection pressure favors outgrowth of MHC-I deficient tumor cells. We performed a genome-scale screen to discover alternative pathways for T cell-mediated killing of MHC-I deficient tumor cells. Autophagy and TNF signaling emerged as top pathways, and inactivation of Rnf31 (TNF signaling) and Atg5 (autophagy) sensitized MHC-I deficient tumor cells to apoptosis by T cell-derived cytokines. Mechanistic studies demonstrated that inhibition of autophagy amplified pro-apoptotic effects of cytokines in tumor cells. Antigens from apoptotic MHC-I deficient tumor cells were efficiently cross-presented by dendritic cells, resulting in heightened tumor infiltration by IFNg and TNFa-producing T cells. Tumors with a substantial population of MHC-I deficient cancer cells could be controlled by T cells when both pathways were targeted using genetic or pharmacological approaches.

2022-09-13 | GSE213078 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data